{"entity":{"id":"trk-950","kind":"drug","name":"TRK-950","aka":[],"tldr":"TRK-950 is an experimental investigational agent whose form is not stated in the registry from Toray Industries in phase 2 trials for gastric & gastro-oesophageal junction cancer and melanoma, aimed at NTRK.","summary":"TRK-950 is an investigational agent whose form is not stated in the registry developed by Toray Industries. Its target is NTRK. ClinicalTrials.gov describes the intervention as: 5 mg/kg or 10 mg/kg IV infusion over 60 minutes on Day 1, 8, 15 and 21 of each 28 day cycle. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in gastric & gastro-oesophageal junction cancer and melanoma. The largest, NCT06038578, plans to enrol 146 participants with primary completion was scheduled for 2026-06-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of TRK-950","url":"https://clinicaltrials.gov/search?intr=TRK-950"},{"label":"Sponsor page","url":"https://www.toray.com"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric","melanoma"],"sections":[],"technologies":[],"targets":["ntrk"],"drugs":[],"companies":["toray-industries"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05423262","nct06038578"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"monoclonal antibody (per the sponsor's pipeline page; form not stated in the registry record)","mechanism":"Investigational agent whose form is not stated in the registry directed at NTRK, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/trk-950/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"target":[{"id":"ntrk","kind":"target","name":"NTRK","route":"/targets/ntrk/"}],"company":[{"id":"toray-industries","kind":"company","name":"Toray Industries","route":"/companies/toray-industries/"}],"trial":[{"id":"nct05423262","kind":"trial","name":"A Study of TRK-950 in Patients With Advanced Solid Tumors","route":"/trials/nct05423262/"},{"id":"nct06038578","kind":"trial","name":"A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer","route":"/trials/nct06038578/"}]}}